Management of metastatic bone disease from breast cancer in two oncological centers in Czech republic - retrospective analysis

Abstract

Bone metastases occur in up to 70% of patients with breast cancer and represent risk of SRE development. Bisphosphonates (BP) decline the occurrence and relapse of SRE.

The aim of study was to evaluate the therapy with BP in patients with bone metastases

Keywords

• bisphosphonates
• bone metastases
• breast cancer
• quality of life